At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 124 enrolled
Drug / intervention
DSXS +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Moderate to Severe Atopic Dermatitis.
In Brief
A Phase 3 clinical trial evaluating DSXS and Placebo for Atopic Dermatitis. Completed, enrolled 124 participants across 1 site.
Detailed Summary
Efficacy and Safety of DSXS (Taro Pharmaceuticals, U.S.A., Inc.) in Patients with Moderate to Severe Atopic Dermatitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartSep 2015
First PostedNov 2015
Primary CompletionJan 2017
Study CompletionAug 2017
TodayJul 2026
First PostedNov 3, 2015
Enrollment StartSep 4, 2015
Primary CompletionJan 17, 2017
Study CompletionAug 29, 2017
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.7 years ago
Interventions
DSXSdrug
Active treatment
Placebodrug
Placebo treatment